Bimekizumab in Psoriasis: 3-Year Outcomes - Quiz - MDSpire

Bimekizumab in Psoriasis: 3-Year Outcomes

Investigators compare patient-reported symptoms and quality-of-life outcomes vs secukinumab.

  • By

  • Kathryn Wighton

  • March 12, 2026

  • 5 min

Share

Original Source(s)

Bimekizumab in Psoriasis: 3-Year Outcomes

  • by Kathryn Wighton

  • March 12, 2026

Related Content

Three-Year Outcomes Reported by Patients Using Bimekizumab for Plaque Psoriasis: Findings from the BE RADIANT Randomized Trial

Evaluation of HS-20137 in Chinese Patients with Moderate-to-Severe Psoriasis: Results from a Phase 2, Randomized, Double-Blind Trial

Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial